دورية أكاديمية
أعرض في EDS

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.

التفاصيل البيبلوغرافية
العنوان: The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.
المؤلفون: Goll JB; The Emmes Company, LLC, Rockville, MD, USA., Jain A; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Jensen TL; The Emmes Company, LLC, Rockville, MD, USA., Assis R; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Nakajima R; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Jasinskas A; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Coughlan L; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA., Cherikh SR; The Emmes Company, LLC, Rockville, MD, USA., Gelber CE; The Emmes Company, LLC, Rockville, MD, USA., Khan S; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Huw Davies D; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA., Meade P; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA., Stadlbauer D; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA.; Moderna Inc., Cambridge, MA, USA., Strohmeier S; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA., Chen WH; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Felgner PL; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA. pfelgner@hs.uci.edu.
المصدر: NPJ vaccines [NPJ Vaccines] 2022 Aug 30; Vol. 7 (1), pp. 103. Date of Electronic Publication: 2022 Aug 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Springer Nature in partnership with the Sealy Center for Vaccine Development, [2016]-
مستخلص: Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.
(© 2022. The Author(s).)
References: Nat Rev Immunol. 2007 Apr;7(4):267-78. (PMID: 17363960)
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17957-17964. (PMID: 32661157)
Immunity. 2017 Oct 17;47(4):599-603. (PMID: 29045889)
J Clin Immunol. 2011 Jun;31(3):443-54. (PMID: 21174144)
Virol J. 2018 Jan 19;15(1):17. (PMID: 29370862)
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41. (PMID: 19004788)
Sci Transl Med. 2014 Jul 23;6(246):246ps8. (PMID: 25101885)
Science. 2015 Sep 18;349(6254):1301-6. (PMID: 26303961)
Vaccines (Basel). 2020 Nov 09;8(4):. (PMID: 33182279)
Lancet Infect Dis. 2013 Jun;13(6):485-96. (PMID: 23518156)
NPJ Vaccines. 2019 Dec 6;4:51. (PMID: 31839997)
Nat Med. 2021 Jan;27(1):106-114. (PMID: 33288923)
Semin Immunol. 2018 Oct;39:14-21. (PMID: 29801750)
Vaccine. 2013 Dec 9;31(51):6122-8. (PMID: 23933368)
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1356-61. (PMID: 14745020)
Front Immunol. 2021 Jan 29;11:607333. (PMID: 33633727)
Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. (PMID: 25734170)
Biotechniques. 2013 Jun;54(6):345-8. (PMID: 23750544)
JAMA. 2015 Jul 21;314(3):237-46. (PMID: 26197184)
PLoS Pathog. 2016 Apr 15;12(4):e1005578. (PMID: 27081859)
Cell Host Microbe. 2018 Jul 11;24(1):18-24. (PMID: 30001520)
Clin Vaccine Immunol. 2015 Nov 11;23(1):73-7. (PMID: 26561390)
Lancet Infect Dis. 2008 Oct;8(10):650-8. (PMID: 18922487)
Sci Rep. 2017 Apr 21;7:46426. (PMID: 28429728)
PLoS One. 2017 Jan 18;12(1):e0167488. (PMID: 28099485)
J Infect Dis. 2011 Mar 1;203(5):666-73. (PMID: 21282194)
Cell Host Microbe. 2016 Jun 8;19(6):800-13. (PMID: 27281570)
Nat Med. 2019 Jun;25(6):962-967. (PMID: 31160818)
Lancet. 2001 Jun 16;357(9272):1937-43. (PMID: 11425416)
Hum Vaccin Immunother. 2013 May;9(5):950-6. (PMID: 23807079)
Pathogens. 2021 Mar 17;10(3):. (PMID: 33802803)
Nat Immunol. 2017 Apr;18(4):456-463. (PMID: 28192417)
Euro Surveill. 2020 Mar;25(10):. (PMID: 32183932)
Sci Transl Med. 2010 Jan 20;2(15):15ra5. (PMID: 20371470)
J Immunol. 2019 Sep 15;203(6):1502-1508. (PMID: 31399519)
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8. (PMID: 25157133)
PLoS Med. 2009 Apr 21;6(4):e1000049. (PMID: 19381279)
JAMA. 2014 Oct 8;312(14):1420-8. (PMID: 25291578)
Am J Epidemiol. 2012 Sep 15;176(6):527-33. (PMID: 22940713)
Vaccines (Basel). 2021 Mar 13;9(3):. (PMID: 33805749)
Vaccine. 2009 Mar 26;27(15):2099-107. (PMID: 19356612)
Viral Immunol. 2018 Mar;31(2):142-149. (PMID: 29356618)
Sci Transl Med. 2021 Mar 3;13(583):. (PMID: 33658355)
Sci Transl Med. 2011 Jun 1;3(85):85ra48. (PMID: 21632986)
Expert Rev Vaccines. 2012 Mar;11(3):349-66. (PMID: 22380826)
J Virol. 2014 Nov;88(22):13260-8. (PMID: 25210189)
mSphere. 2018 Dec 12;3(6):. (PMID: 30541779)
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182. (PMID: 32078591)
Nat Struct Mol Biol. 2016 Sep;23(9):811-820. (PMID: 27478931)
Open Forum Infect Dis. 2014 Oct 08;1(3):ofu091. (PMID: 25734159)
معلومات مُعتمدة: HHSN272200800057C United States AI NIAID NIH HHS; 75N93021C00012 United States AI NIAID NIH HHS; HHSN272200800013C United States AI NIAID NIH HHS; HHSN272201300022C United States AI NIAID NIH HHS; HHSN272201300022I United States AI NIAID NIH HHS
تواريخ الأحداث: Date Created: 20220830 Latest Revision: 20240517
رمز التحديث: 20240517
مُعرف محوري في PubMed: PMC9427073
DOI: 10.1038/s41541-022-00524-7
PMID: 36042229
قاعدة البيانات: MEDLINE
الوصف
تدمد:2059-0105
DOI:10.1038/s41541-022-00524-7